
    
      Primary objective:

      To investigate the safety and efficacy of autologous or HLA-haploidentical Allo-CD19-CAR-T
      cells in the treatment of patients with relapsed or refractory acute B-cell lymphoblastic
      leukemia.

      Secondary objective:

      To Assess the patient's quality of life after receiving the treatment.
    
  